Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, S
Right arrow Articles by Kim, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, S
Right arrow Articles by Kim, C.
Haematologica, Vol 91, Issue 5, 671-674
Copyright © 2006 by Ferrata Storti Foundation

Clinical Trial

The significance of minimal residual disease kinetics in adults with newly diagnosed PML-RARalpha-positive acute promyelocytic leukemia: results of a prospective trial

S Lee, YJ Kim, KS Eom, CK Min, HJ Kim, SG Cho, JW Lee, WS Min, and CC Kim

Catholic Hematopoietic Stem Cell Transplantation Center, College of Medicine, The Catholic University of Korea, Seoul, Korea. leeseok@catholic.ac.kr

Seventy adults with acute promyelocytic leukemia were studied to clarify the significance of the level and kinetics of minimal residual disease (MRD) over their entire treatment course by realtime quantitative polymerase chain reaction. At a median follow-up of 44 months, nine relapses had occurred. The 5-year probabilities of relapse and disease-free survival were 17.3+/-5.4% and 81.5+/-5.4%, respectively. A MRD level of >10-3 after first consolidation was the most powerful predictor of relapse (85.7+/-13.2% versus 7.3+/-4.1%, p<0.001) and disease-free survival (14.3+/-13.2% versus 91.2%+/-4.3%, p<0.001). Prospective MRD monitoring may allow us to identify subgroups of patients at high risk of relapse earlier during treatment.


This article has been cited by other articles:


Home page
 haematolHome page
F. Lo-Coco, E. Ammatuna, and M. A. Sanz
Current treatment of acute promyelocytic leukemia
Haematologica, March 1, 2007; 92(3): 289 - 291.
[Full Text] [PDF]

Home page
 haematolHome page
C. Santamaria, M. C. Chillon, C. Fernandez, P. Martin-Jimenez, A. Balanzategui, R. Garcia Sanz, J. F. San Miguel, and M.-G. Gonzalez
Using quantification of the PML-RAR{alpha} transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia
Haematologica, March 1, 2007; 92(3): 315 - 322.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
F. Lo-Coco and E. Ammatuna
The Biology of Acute Promyelocytic Leukemia and Its Impact on Diagnosis and Treatment
Hematology, January 1, 2006; 2006(1): 156 - 161.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.